Clinical Reviews in Allergy & Immunology

, Volume 51, Issue 2, pp 216–229 | Cite as

HAE Pathophysiology and Underlying Mechanisms

Article
First Online:

Abstract

Remarkable progress in understanding the pathophysiology and underlying mechanisms of hereditary angioedema has led to the development of effective treatment for this disorder. Progress in three separate areas has catalyzed our understanding of hereditary angioedema. The first is the recognition that HAE type I and type II result from a deficiency in the plasma level of functional C1 inhibitor. This observation has led to a detailed understanding of the SERPING1 mutations responsible for this deficiency as well as the molecular regulation of C1 inhibitor expression and function. The second is that the fundamental cause of swelling is enhanced contact system activation leading to increased generation of bradykinin. Substantial progress has been made in defining the parameters regulating bradykinin generation and catabolism as well as the receptors that transduce the biologic effects of kinins. The third is the understanding that tissue swelling in hereditary angioedema primarily involves the function of endothelial cell adherens junctions. This knowledge is driving increased attention to the role of endothelial biology in determining disease activity in hereditary angioedema. While there has been considerable progress made, large gaps still remain in our knowledge. Important areas that remain poorly understood include the factors that lead to very low plasma functional C1 inhibitor levels, the triggers of contact system activation in hereditary angioedema, and the role of the bradykinin B1 receptor. The phenotypic variability of hereditary angioedema has been extensively documented but never understood. The mechanisms discussed in this chapter likely contribute to this variability. Future progress in understanding these mechanisms should provide new means to improve the diagnosis and treatment of hereditary angioedema.

Keywords

Hereditary angioedema C1 inhibitor Bradykinin Bradykinin B2 receptor Bradykinin B1 receptor Endothelial cell VE-cadherin Vascular permeability 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Osler W (1888) Hereditary angio-neurotic oedema. Am J Med Sci 95(4):362–367CrossRefGoogle Scholar
  2. 2.
    Landerman NS, Webster ME, Becker EL, Ratcliffe HE (1962) Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J Allergy 33:330–341PubMedCrossRefGoogle Scholar
  3. 3.
    Donaldson VH, Evans RR (1963) A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C’1-esterase. Am J Med 35:37–44PubMedCrossRefGoogle Scholar
  4. 4.
    Rosen FS, Pensky J, Donaldson V, Charache P (1965) Hereditary angioneurotic edema: two genetic variants. Science 148:957–958PubMedCrossRefGoogle Scholar
  5. 5.
    Bork K, Barnstedt SE, Koch P, Traupe H (2000) Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 356(9225):213–217PubMedCrossRefGoogle Scholar
  6. 6.
    Binkley KE, Davis A 3rd (2000) Clinical, biochemical, and genetic characterization of a novel estrogen- dependent inherited form of angioedema. J Allergy Clin Immunol 106(3):546–550PubMedCrossRefGoogle Scholar
  7. 7.
    Bock SC, Skriver K, Nielsen E, Thogersen HC, Wiman B, Donaldson VH, Eddy RL, Marrinan J, Radziejewska E, Huber R, Shows TB, Magnusson S (1986) Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry 25:4292–4301PubMedCrossRefGoogle Scholar
  8. 8.
    Davis AE III (1988) C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol 6:595–628PubMedCrossRefGoogle Scholar
  9. 9.
    Bissler JJ, Aulak KS, Donaldson VH, Rosen FS, Cicardi M, Harrison RA, Davis AE 3rd (1997) Molecular defects in hereditary angioneurotic edema. Proc Assoc Am Physicians 109(2):164–173PubMedGoogle Scholar
  10. 10.
    Verpy E, Biasotto M, Brai M, Misiano G, Meo T, Tosi M (1996) Exhaustive mutation scanning by fluorescence-assisted mismatch analysis discloses new genotype-phenotype correlations in angiodema [see comments]. Am J Hum Genet 59(2):308–319PubMedPubMedCentralGoogle Scholar
  11. 11.
    Zuraw BL, Herschbach J (2000) Detection of C1 inhibitor mutations in patients with hereditary angioedema. J Allergy Clin Immunol 105(3):541–546PubMedCrossRefGoogle Scholar
  12. 12.
    Huber R, Carrell RW (1989) Implications of the three-dimensional structure of alpha1-antitrypsin for structure and function of serpins. Biochemistry 28:8951–8966PubMedCrossRefGoogle Scholar
  13. 13.
    Gettins PG (2002) Serpin structure, mechanism, and function. Chem Rev 102(12):4751–4804PubMedCrossRefGoogle Scholar
  14. 14.
    Aulak KS, Pemberton PA, Rosen FS, Carrell RW, Lachmann PJ, Harrison RA (1988) Dysfunctional C1-inhibitor(At), isolated from a type II hereditary-angio-oedema plasma, contains a P1 `reactive centre’ (Arg444->His) mutation. Biochem J 253:615–618PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Donaldson VH, Harrison RA, Rosen FS, Bing DH, Kindness G, Canar J, Wagner CJ, Awad S (1985) Variability in purified dysfunctional C1-inhibitor proteins from patients with hereditary angioneurotic edema. Functional and analytical gel studies. J Clin Invest 75:124–132PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Donaldson VH, Bissler JJ (1992) C1 inhibitors and their genes: an update. J Lab Clin Med 119:330–333PubMedGoogle Scholar
  17. 17.
    Frangi D, Aulak KS, Cicardi M, Harrison RA, Davis AE III (1992) A dysfunctional C1 inhibitor protein with a new reactive center mutation (Arg-444–>Leu). FEBS Lett 301:34–36PubMedCrossRefGoogle Scholar
  18. 18.
    Skriver K, Radziejewska E, Silbermann JA, Donaldson VH, Bock SC (1989) CpG mutations in the reactive site of human C1 inhibitor. J Biol Chem 264:3066–3071PubMedGoogle Scholar
  19. 19.
    Parad RB, Kramer J, Strunk RC, Rosen FS, Davis AE III (1990) Dysfunctional C1 inhibitor Ta: deletion of Lys-251 results in acquisition of an N-glycosylation site. Proc Natl Acad Sci U S A 87:6786–6790PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Lachmann PJ, Rosen FS (1984) The catabolism of C1-inhibitor and the pathogenesis of hereditary angio-edema. Acta Pathol Microbiol Scand 92:35–39Google Scholar
  21. 21.
    Rosen FS, Alper CA, Pensky J, Klemperer MR, Donaldson VH (1971) Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema. J Clin Invest 50:2143–2149PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Davis AE 3rd (2006) Mechanism of angioedema in first complement component inhibitor deficiency. Immunol Allergy Clin N Am 26(4):633–651CrossRefGoogle Scholar
  23. 23.
    Spath PJ, Wuthrich B, Butler R (1984) Quantification of C1-inhibitor functional activities by immunodiffusion assay in plasma of patients with hereditary angioedema - evidence of a functionally critical level of C1-inhibitor concentration. Complement 1:147–159PubMedGoogle Scholar
  24. 24.
    Zuraw BL, Cicardi M, Longhurst HJ, Bernstein JA, Li HH, Magerl M, Martinez-Saguer I, Rehman SM, Staubach P, Feuersenger H, Parasrampuria R, Sidhu J, Edelman J, Craig T (2015) Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate. Allergy 70(10):1319–1328. doi: 10.1111/all.12658 PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Quastel M, Harrison R, Cicardi M, Alper CA, Rosen FS (1983) Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema. J Clin Invest 71(4):1041–1046PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Agostoni A, Aygoren-Pursun E, Binkley KE, Blanch A, Bork K, Bouillet L, Bucher C, Castaldo AJ, Cicardi M, Davis AE, De Carolis C, Drouet C, Duponchel C, Farkas H, Fay K, Fekete B, Fischer B, Fontana L, Fust G, Giacomelli R, Groner A, Hack CE, Harmat G, Jakenfelds J, Juers M, Kalmar L, Kaposi PN, Karadi I, Kitzinger A, Kollar T, Kreuz W, Lakatos P, Longhurst HJ, Lopez-Trascasa M, Martinez-Saguer I, Monnier N, Nagy I, Nemeth E, Nielsen EW, Nuijens JH, O’Grady C, Pappalardo E, Penna V, Perricone C, Perricone R, Rauch U, Roche O, Rusicke E, Spath PJ, Szendei G, Takacs E, Tordai A, Truedsson L, Varga L, Visy B, Williams K, Zanichelli A, Zingale L (2004) Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 114(3 Suppl):S51–131PubMedCrossRefGoogle Scholar
  27. 27.
    Kunschak M, Engl W, Maritsch F, Rosen FS, Eder G, Zerlauth G, Schwarz HP (1998) A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion 38(6):540–549PubMedCrossRefGoogle Scholar
  28. 28.
    Zuraw BL, Curd JG (1986) Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients. J Clin Invest 78:567–575PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Ernst SC, Circolo A, Davis AE 3rd, Gheesling-Mullis K, Fliesler M, Strunk RC (1996) Impaired production of both normal and mutant C1 inhibitor proteins in type I hereditary angioedema with a duplication in exon 8. J Immunol 157(1):405–410PubMedGoogle Scholar
  30. 30.
    Kramer J, Rosen FS, Colten HR, Rajczy K, Strunk RC (1993) Transinhibition of C1 inhibitor synthesis in type I hereditary angioneurotic edema. J Clin Invest 91:1258–1262PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Zuraw BL, Lotz M (1990) Regulation of the hepatic synthesis of C1 inhibitor by the hepatocyte stimulating factors interleukin 6 and interferon gamma. J Biol Chem 265:12664–12670PubMedGoogle Scholar
  32. 32.
    Lotz M, Zuraw BL (1987) Interferon gamma is a major regulator of C1-inhibitor synthesis by human blood monocytes. J Immunol 139:3382–3387PubMedGoogle Scholar
  33. 33.
    Bensa JC, Reboul A, Colomb MG (1983) Biosynthesis in vitro of complement subcomponents C1q, C1s, and C1 inhibitor by resting and stimulated human monocytes. Biochem J 216:385–392PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Yeung-Laiwah AC, Jones L, Hamilton AO, Whaley K (1985) Complement-subcomponent-C1-inhibitor synthesis by human monocytes. Biochem J 226:199–205PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Randazzo BP, Dattwyler RJ, Kaplan AP, Ghebrehiwet B (1985) Synthesis of C1 inhibitor (C1-INA) by a human monocyte-like cell line, U937. J Immunol 135:1313–1319PubMedGoogle Scholar
  36. 36.
    Schmaier AH, Murray SC, Heda GD, Farber A, Kuo A, McCrae K, Cines DB (1989) Synthesis and expression of C1 inhibitor by human umbilical vein endothelial cells. J Biol Chem 264:18173–18179PubMedGoogle Scholar
  37. 37.
    Katz Y, Strunk RC (1988) Synovial fibroblast-like cells synthesize seven proteins of the complement system. Arthritis Rheum 31:1365–1370PubMedCrossRefGoogle Scholar
  38. 38.
    Schmaier AH, Amenta S, Xiong T, Heda GD, Gewirtz AM (1993) Expression of platelet C1 inhibitor. Blood 82(2):465–474PubMedGoogle Scholar
  39. 39.
    Walker DG, Yasuhara O, Patston PA, McGeer EG, McGeer PL (1995) Complement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer disease. Brain Res 675(1–2):75–82PubMedCrossRefGoogle Scholar
  40. 40.
    Klausegger A, Wiednig M, Urban C, Lackner H, Reiter H, Bauer JW, Aberer W (2012) Successful allogeneic cord blood transplantation in a patient with Evans syndrome leads to correction of hereditary angioedema type I as secondary effect. Bone Marrow Transplant 47(9):1259–1261. doi: 10.1038/bmt.2012.7 PubMedCrossRefGoogle Scholar
  41. 41.
    Heda GD, Mardente S, Weiner L, Schmaier AH (1990) Interferon gamma increases in vitro and in vivo expression of C1 inhibitor. Blood 75:2401–2407PubMedGoogle Scholar
  42. 42.
    Falus A, Fehér KG, Walcz E, Brozik M, Füst G, Hidvégi T, Fehér T, Merétey K (1990) Hormonal regulation of complement biosynthesis in human cell lines–I. Androgens and gamma-interferon stimulate the biosynthesis and gene expression of C1 inhibitor in human cell lines U937 and HepG2. Mol Immunol 27:191–195PubMedCrossRefGoogle Scholar
  43. 43.
    Al Abdullah IH, Sim RB, Sheil J, Greally JF (1984) The effect of danazol on the production of C1 inhibitor in the Guinea pig. Complement 1:27–35PubMedGoogle Scholar
  44. 44.
    Lappin DF, McPhaden AR, Yap PL, Carter PE, Birnie GD, Fothergill JE, Whaley K (1989) Monocyte C1-inhibitor synthesis in patients with C1-inhibitor deficiency. Eur J Clin Investig 19:45–52CrossRefGoogle Scholar
  45. 45.
    Pappalardo E, Zingale LC, Cicardi M (2003) Increased expression of C1-inhibitor mRNA in patients with hereditary angioedema treated with Danazol. Immunol Lett 86(3):271–276PubMedCrossRefGoogle Scholar
  46. 46.
    Cicardi M, Igarashi T, Rosen FS, Davis AE III (1987) Molecular basis for the deficiency of complement 1 inhibitor in type 1 hereditary angioneurotic edema. J Clin Invest 79:698–702PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Kramer J, Katz Y, Rosen FS, Davis AE III, Strunk RC (1991) Synthesis of C1 inhibitor in fibroblasts from patients with type I and type II hereditary angioneurotic edema. J Clin Invest 87:1614–1620PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Csuka D, Fust G, Farkas H, Varga L (2011) Parameters of the classical complement pathway predict disease severity in hereditary angioedema. Clin Immunol 139(1):85–93. doi: 10.1016/j.clim.2011.01.003 PubMedCrossRefGoogle Scholar
  49. 49.
    Christiansen SC, Zuraw BL, Proud D, Cochrane CG (1989) Inhibition of human bronchial kallikrein in asthma. Am Rev Respir Dis 139(5):1125–1131. doi: 10.1164/ajrccm/139.5.1125 PubMedCrossRefGoogle Scholar
  50. 50.
    Christiansen SC, Proud D, Cochrane CG (1987) Detection of tissue kallikrein in the bronchoalveolar lavage fluid of asthmatic subjects. J Clin Invest 79:188–197PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Donaldson VH, Rosen FS, Bing DH (1977) Role of the second component of complement (C2) and plasmin in kinin release in hereditary angioneurotic edema (H.A.N.E.) plasma. Trans Assoc Am Phys 90:174–183PubMedGoogle Scholar
  52. 52.
    Curd JG, Prograis LJ Jr, Cochrane CG (1980) Detection of active kallikein in induced blister fluids of hereditary angioedema patients. J Exp Med 152:742–747PubMedCrossRefGoogle Scholar
  53. 53.
    Curd JG, Yelvington M, Burridge N, Stimler NP, Gerard C, Prograis LJ Jr, Cochrane CG (1982) Generation of bradykinin during incubation of hereditary angioedema plasma. Mol Immunol 19:1365–1365CrossRefGoogle Scholar
  54. 54.
    Fields T, Ghebrehiwet B, Kaplan AP (1983) Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of "spontaneous" formation of bradykinin. J Allergy Clin Immunol 72:54–60PubMedCrossRefGoogle Scholar
  55. 55.
    Schapira M, Silver LD, Scott CF, Schmaier AH, Prograis LJ, Curd JG, Colman RW (1983) Prekallikrein activation and high- molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med 308:1050–1054PubMedCrossRefGoogle Scholar
  56. 56.
    Lammle B, Zuraw BL, Heeb MJ, Schwarz HP, Berrettini M, Curd JG, Griffin JH (1988) Detection and quantitation of cleaved and uncleaved high molecular weight kininogen in plasma by ligand blotting with radiolabeled plasma prekallikrein or factor XI. Thromb Haemost 59:151–161PubMedGoogle Scholar
  57. 57.
    Berrettini M, Lammle B, White T, Heeb MJ, Schwarz HP, Zuraw B, Curd J, Griffin JH (1986) Detection of in vitro and in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies. Blood 68(2):455–462PubMedGoogle Scholar
  58. 58.
    Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A (1998) Plasma bradykinin in angio-oedema. Lancet 351(9117):1693–1697PubMedCrossRefGoogle Scholar
  59. 59.
    Nussberger J, Cugno M, Cicardi M, Agostoni A (1999) Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol 104(6):1321–1322PubMedCrossRefGoogle Scholar
  60. 60.
    Dewald G, Bork K (2006) Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 343(4):1286–1289PubMedCrossRefGoogle Scholar
  61. 61.
    Cichon S, Martin L, Hennies HC, Muller F, Van Driessche K, Karpushova A, Stevens W, Colombo R, Renne T, Drouet C, Bork K, Nothen MM (2006) Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 79(6):1098–1104PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Bjorkqvist J, de Maat S, Lewandrowski U, Di Gennaro A, Oschatz C, Schonig K, Nothen MM, Drouet C, Braley H, Nolte MW, Sickmann A, Panousis C, Maas C, Renne T (2015) Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III. J Clin Invest 125(8):3132–3146. doi: 10.1172/JCI77139 PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Bouillet L, Ponard D, Rousset H, Cichon S, Drouet C (2007) A case of hereditary angio-oedema type III presenting with C1-inhibitor cleavage and a missense mutation in the F12 gene. Br J Dermatol 156(5):1063–1065. doi: 10.1111/j.1365-2133.2007.07778.x PubMedCrossRefGoogle Scholar
  64. 64.
    Zuraw BL, Sugimoto S, Curd J (1986) Modified inactive C1 inhibitor (C1inh) is generated during attacks of angioedema in hereditary angioedema (HAE). J Allergy Clin Immunol 77:188–188Google Scholar
  65. 65.
    Defendi F, Charignon D, Ghannam A, Baroso R, Csopaki F, Allegret-Cadet M, Ponard D, Favier B, Cichon S, Nicolie B, Fain O, Martin L, Drouet C, National Reference Centre for Angioedema C (2013) Enzymatic assays for the diagnosis of bradykinin-dependent angioedema. PLoS One 8(8):e70140. doi: 10.1371/journal.pone.0070140 PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Joseph K, Tholanikunnel BG, Wolf B, Bork K, Kaplan AP (2015) Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels. J Allergy Clin Immunol. doi: 10.1016/j.jaci.2015.07.041 PubMedCentralGoogle Scholar
  67. 67.
    Kaplan AP, Austen KF (1971) A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med 133(4):696–712PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Zotter Z, Csuka D, Szabo E, Czaller I, Nebenfuhrer Z, Temesszentandrasi G, Fust G, Varga L, Farkas H (2014) The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency. Orphanet J Rare Dis 9(1):44. doi: 10.1186/1750-1172-9-44 PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Cochrane CG, Griffin JH (1982) The biochemistry and pathophysiology of the contact system of plasma. Adv Immunol 33:241–306PubMedCrossRefGoogle Scholar
  70. 70.
    White-Adams TC, Berny MA, Patel IA, Tucker EI, Gailani D, Gruber A, McCarty OJ (2010) Laminin promotes coagulation and thrombus formation in a factor XII-dependent manner. J Thromb Haemost 8(6):1295–1301. doi: 10.1111/j.1538-7836.2010.03850.x PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    van der Meijden PE, Munnix IC, Auger JM, Govers-Riemslag JW, Cosemans JM, Kuijpers MJ, Spronk HM, Watson SP, Renne T, Heemskerk JW (2009) Dual role of collagen in factor XII-dependent thrombus formation. Blood 114(4):881–890. doi: 10.1182/blood-2008-07-171066 PubMedCrossRefGoogle Scholar
  72. 72.
    Bork K, Meng G, Staubach P, Hardt J (2006) Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 119(3):267–274PubMedCrossRefGoogle Scholar
  73. 73.
    Longhurst H, Cicardi M (2012) Hereditary angio-oedema. Lancet 379(9814):474–481. doi: 10.1016/S0140-6736(11)60935-5 PubMedCrossRefGoogle Scholar
  74. 74.
    Agostoni A, Cicardi M (1992) Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 71(4):206–215CrossRefGoogle Scholar
  75. 75.
    Bouillet L, Gompel A (2013) Hereditary angioedema in women: specific challenges. Immunol Allergy Clin N Am 33(4):505–511. doi: 10.1016/j.iac.2013.07.006 CrossRefGoogle Scholar
  76. 76.
    Martinez-Saguer I, Rusicke E, Aygoren-Pursun E, Heller C, Klingebiel T, Kreuz W (2010) Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. Am J Obstet Gynecol 203(2):131 e131–131 e137. doi: 10.1016/j.ajog.2010.03.003 CrossRefGoogle Scholar
  77. 77.
    Czaller I, Visy B, Csuka D, Fust G, Toth F, Farkas H (2010) The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey. Eur J Obstet Gynecol Reprod Biol 152(1):44–49. doi: 10.1016/j.ejogrb.2010.05.008 PubMedCrossRefGoogle Scholar
  78. 78.
    Farsetti A, Misiti S, Citarella F, Felici A, Andreoli M, Fantoni A, Sacchi A, Pontecorvi A (1995) Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology 136(11):5076–5083PubMedGoogle Scholar
  79. 79.
    Brunnee T, Reddigari SR, Shibayama Y, Kaplan AP, Silverberg M (1997) Mast cell derived heparin activates the contact system: a link to kinin generation in allergic reactions. Clin Exp Allergy 27(6):653–663PubMedCrossRefGoogle Scholar
  80. 80.
    Oschatz C, Maas C, Lecher B, Jansen T, Bjorkqvist J, Tradler T, Sedlmeier R, Burfeind P, Cichon S, Hammerschmidt S, Muller-Esterl W, Wuillemin WA, Nilsson G, Renne T (2011) Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 34(2):258–268. doi: 10.1016/j.immuni.2011.02.008 PubMedCrossRefGoogle Scholar
  81. 81.
    Sala-Cunill A, Bjorkqvist J, Senter R, Guilarte M, Cardona V, Labrador M, Nickel KF, Butler L, Luengo O, Kumar P, Labberton L, Long A, Di Gennaro A, Kenne E, Jamsa A, Krieger T, Schluter H, Fuchs T, Flohr S, Hassiepen U, Cumin F, McCrae K, Maas C, Stavrou E, Renne T (2015) Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions. J Allergy Clin Immunol 135(4):1031–1043 e1036. doi: 10.1016/j.jaci.2014.07.057 PubMedCrossRefGoogle Scholar
  82. 82.
    Ishizaka T, Iwata M, Ishizaka K (1985) Release of histamine and arachidonate from mouse mast cells induced by glycosylation-enhancing factor and bradykinin. J Immunol 134:1880–1887PubMedGoogle Scholar
  83. 83.
    Lawrence ID, Warner JA, Cohan VL, Lichtenstein LM, Kagey-Sobotka A, Vavrek RJ, Stewart JM, Proud D (1989) Induction of histamine release from human skin mast cells by bradykinin analogs. Biochem Pharmacol 38:227–233PubMedCrossRefGoogle Scholar
  84. 84.
    Maurer M, Church MK (2012) Inflammatory skin responses induced by icatibant injection are mast cell mediated and attenuated by H(1)-antihistamines. Exp Dermatol 21(2):154–155. doi: 10.1111/j.1600-0625.2011.01410.x PubMedCrossRefGoogle Scholar
  85. 85.
    Morrison DC, Cochrane CG (1974) Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins). J Exp Med 140(3):797–811PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Maas C, Govers-Riemslag JW, Bouma B, Schiks B, Hazenberg BP, Lokhorst HM, Hammarstrom P, ten Cate H, de Groot PG, Bouma BN, Gebbink MF (2008) Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 118(9):3208–3218. doi: 10.1172/JCI35424 PubMedPubMedCentralGoogle Scholar
  87. 87.
    Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, Song Y, Tzima E, Kennerknecht E, Niepmann M, von Bruehl ML, Sedding D, Massberg S, Gunther A, Engelmann B, Preissner KT (2007) Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A 104(15):6388–6393. doi: 10.1073/pnas.0608647104 PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Muller F, Mutch NJ, Schenk WA, Smith SA, Esterl L, Spronk HM, Schmidbauer S, Gahl WA, Morrissey JH, Renne T (2009) Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 139(6):1143–1156. doi: 10.1016/j.cell.2009.11.001 PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Van Der Meijden PE, Van Schilfgaarde M, Van Oerle R, Renne T, ten Cate H, Spronk HM (2012) Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost 10(7):1355–1362. doi: 10.1111/j.1538-7836.2012.04758.x CrossRefGoogle Scholar
  90. 90.
    Long YM, Zhao XC, Clermont AC, Zhou QF, Liu Q, Feener EP, Yan B, Jiang GB (2015) Negatively charged silver nanoparticles cause retinal vascular permeability by activating plasma contact system and disrupting adherens junction. Nanotoxicology:1–11. doi: 10.3109/17435390.2015.1088589
  91. 91.
    Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL (2005) International union of pharmacology. XLV classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 57(1):27–77. doi: 10.1124/pr.57.1.2 PubMedCrossRefGoogle Scholar
  92. 92.
    Israili ZH, Hall WD (1992) Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 117:234–242PubMedCrossRefGoogle Scholar
  93. 93.
    Brown NJ, Snowden M, Griffin MR (1997) Recurrent angiotensin-converting enzyme inhibitor–associated angioedema. JAMA 278(3):232–233PubMedCrossRefGoogle Scholar
  94. 94.
    Agostoni A, Cicardi M, Cugno M, Zingale LC, Gioffre D, Nussberger J (1999) Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology 44(1–2):21–25PubMedCrossRefGoogle Scholar
  95. 95.
    Agostoni A, Cicardi M (1991) Contraindications to the use of ACE inhibitors in patients with C1 esterase inhibitor deficiency. Am J Med 90:278–278PubMedCrossRefGoogle Scholar
  96. 96.
    Cilia La Corte AL, Carter AM, Rice GI, Duan QL, Rouleau GA, Adam A, Grant PJ, Hooper NM (2011) A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor-induced angioedema. Hum Mutat 32(11):1326–1331. doi: 10.1002/humu.21579 PubMedCrossRefGoogle Scholar
  97. 97.
    Drouet C, Desormeaux A, Robillard J, Ponard D, Bouillet L, Martin L, Kanny G, Moneret-Vautrin DA, Bosson JL, Quesada JL, Lopez-Trascasa M, Adam A (2008) Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. J Allergy Clin Immunol 121(2):429–433. doi: 10.1016/j.jaci.2007.10.048 PubMedCrossRefGoogle Scholar
  98. 98.
    Duan QL, Binkley K, Rouleau GA (2009) Genetic analysis of factor XII and bradykinin catabolic enzymes in a family with estrogen-dependent inherited angioedema. J Allergy Clin Immunol 123(4):906–910. doi: 10.1016/j.jaci.2008.12.010 PubMedCrossRefGoogle Scholar
  99. 99.
    Pan ZK, Christiansen SC, Ptasznik A, Zuraw BL (1999) Requirement of phosphatidylinositol 3-kinase activity for bradykinin stimulation of NF-kappa B activation in cultured human epithelial cells. J Biol Chem 274:9918–9922PubMedCrossRefGoogle Scholar
  100. 100.
    Pan ZK, Ye RD, Christiansen SC, Jagels MA, Bokoch GM, Zuraw BL (1998) Role of the rho GTPase in bradykinin stimulated NF-kB activation and interleukin-1b Gene expression in cultured human epithelial cells. J Immunol 160:3038–3045PubMedGoogle Scholar
  101. 101.
    Pan ZK, Zuraw BL, Lung CC, Prossnitz ER, Browning DD, Ye RD (1996) Bradykinin stimulates NF-kB activation and interleukin-1b gene expression in cultured human fibroblasts. J Clin Invest 98(9):2042–2049PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE 3rd (2002) Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 109(8):1057–1063PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Cicardi M, Banerji A, Bracho F, Malbran A, Rosenkranz B, Riedl M, Bork K, Lumry W, Aberer W, Bier H, Bas M, Greve J, Hoffmann TK, Farkas H, Reshef A, Ritchie B, Yang W, Grabbe J, Kivity S, Kreuz W, Levy RJ, Luger T, Obtulowicz K, Schmid-Grendelmeier P, Bull C, Sitkauskiene B, Smith WB, Toubi E, Werner S, Anne S, Bjorkander J, Bouillet L, Cillari E, Hurewitz D, Jacobson KW, Katelaris CH, Maurer M, Merk H, Bernstein JA, Feighery C, Floccard B, Gleich G, Hebert J, Kaatz M, Keith P, Kirkpatrick CH, Langton D, Martin L, Pichler C, Resnick D, Wombolt D, Fernandez Romero DS, Zanichelli A, Arcoleo F, Knolle J, Kravec I, Dong L, Zimmermann J, Rosen K, Fan WT (2010) Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 363(6):532–541. doi: 10.1056/NEJMoa0906393 PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Bossi F, Fischetti F, Regoli D, Durigutto P, Frossi B, Gobeil F Jr, Ghebrehiwet B, Peerschke EI, Cicardi M, Tedesco F (2009) Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. J Allergy Clin Immunol 124(6):1303–1310 e1304. doi: 10.1016/j.jaci.2009.08.007 PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Hofman ZLM, Relan A, Zeerleeder S, Drouet C, Zuraw BL, Hack E (2016) Angioedema attacks of hereditary angioedema: local manifestations of a systemic activation process. J Allergy Clin Immunol in revisionGoogle Scholar
  106. 106.
    Aptecar E, Lecorvoisier P, Teiger E, Garot P, Dupouy P, Sediame S, Vermes E, Loisance D, Hittinger L, Dubois-Rande JL, Montagne O (2006) Coronary vasomotor response to the selective B1-kinin-receptor agonist Des-Arg9-bradykinin in humans. J Heart Lung Transplant: Off Publ Int Soc Heart Transplant 25(2):187–194. doi: 10.1016/j.healun.2005.08.020 CrossRefGoogle Scholar
  107. 107.
    Wu H, Roks AJ, Leijten FP, Garrelds IM, Musterd-Bhaggoe UM, van den Bogaerdt AJ, de Maat MP, Simoons ML, Danser AH, Oeseburg H (2014) Genetic variation and gender determine bradykinin type 1 receptor responses in human tissue: implications for the ACE-inhibitor-induced effects in patients with coronary artery disease. Clin Sci (Lond) 126(6):441–449. doi: 10.1042/CS20130204 CrossRefGoogle Scholar
  108. 108.
    Leeb-Lundberg LM, Kang DS, Lamb ME, Fathy DB (2001) The human B1 bradykinin receptor exhibits high ligand-independent, constitutive activity. Roles of residues in the fourth intracellular and third transmembrane domains. J Biol Chem 276(12):8785–8792PubMedCrossRefGoogle Scholar
  109. 109.
    Ni A, Chao L, Chao J (1998) Transcription factor nuclear factor kappaB regulates the inducible expression of the human B1 receptor gene in inflammation. J Biol Chem 273(5):2784–2791PubMedCrossRefGoogle Scholar
  110. 110.
    Christiansen SC, Eddleston J, Woessner KM, Chambers SS, Ye R, Pan ZK, Zuraw BL (2002) Up-regulation of functional kinin B1 receptors in allergic airway inflammation. J Immunol 169(4):2054–2060PubMedCrossRefGoogle Scholar
  111. 111.
    Zhang X, Tan F, Zhang Y, Skidgel RA (2008) Carboxypeptidase M and kinin B1 receptors interact to facilitate efficient b1 signaling from B2 agonists. J Biol Chem 283(12):7994–8004. doi: 10.1074/jbc.M709837200 PubMedCrossRefGoogle Scholar
  112. 112.
    Zhang X, Tan F, Brovkovych V, Zhang Y, Skidgel RA (2011) Cross-talk between carboxypeptidase M and the kinin B1 receptor mediates a new mode of G protein-coupled receptor signaling. J Biol Chem 286(21):18547–18561. doi: 10.1074/jbc.M110.214940 PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Zhang X, Tan F, Skidgel RA (2013) Carboxypeptidase M is a positive allosteric modulator of the kinin B1 receptor. J Biol Chem 288(46):33226–33240. doi: 10.1074/jbc.M113.520791 PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Komarova Y, Malik AB (2010) Regulation of endothelial permeability via paracellular and transcellular transport pathways. Annu Rev Physiol 72:463–493. doi: 10.1146/annurev-physiol-021909-135833 PubMedCrossRefGoogle Scholar
  115. 115.
    Dejana E, Giampietro C (2012) Vascular endothelial-cadherin and vascular stability. Curr Opin Hematol 19(3):218–223. doi: 10.1097/MOH.0b013e3283523e1c PubMedCrossRefGoogle Scholar
  116. 116.
    Dejana E, Tournier-Lasserve E, Weinstein BM (2009) The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. Dev Cell 16(2):209–221. doi: 10.1016/j.devcel.2009.01.004 PubMedCrossRefGoogle Scholar
  117. 117.
    Baumgartner W, Schutz GJ, Wiegand J, Golenhofen N, Drenckhahn D (2003) Cadherin function probed by laser tweezer and single molecule fluorescence in vascular endothelial cells. J Cell Sci 116(Pt 6):1001–1011PubMedCrossRefGoogle Scholar
  118. 118.
    Huber AH, Stewart DB, Laurents DV, Nelson WJ, Weis WI (2001) The cadherin cytoplasmic domain is unstructured in the absence of beta-catenin. A possible mechanism for regulating cadherin turnover. J Biol Chem 276(15):12301–12309. doi: 10.1074/jbc.M010377200 PubMedCrossRefGoogle Scholar
  119. 119.
    Davis MA, Ireton RC, Reynolds AB (2003) A core function for p120-catenin in cadherin turnover. J Cell Biol 163(3):525–534. doi: 10.1083/jcb.200307111 PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Pokutta S, Weis WI (2007) Structure and mechanism of cadherins and catenins in cell–cell contacts. Annu Rev Cell Dev Biol 23:237–261. doi: 10.1146/annurev.cellbio.22.010305.104241 PubMedCrossRefGoogle Scholar
  121. 121.
    Dyer LA, Patterson C (2010) Development of the endothelium: an emphasis on heterogeneity. Semin Thromb Hemost 36(3):227–235. doi: 10.1055/s-0030-1253446 PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Schmaier AH, Kuo A, Lundberg D, Murray S, Cines DB (1988) The expression of high molecular weight kininogen on human umbilical vein endothelial cells. J Biol Chem 263:16327–16333PubMedGoogle Scholar
  123. 123.
    Joseph K, Ghebrehiwet B, Peerschke EI, Reid KB, Kaplan AP (1996) Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular "heads" of C1q (gC1q-R). Proc Natl Acad Sci U S A 93(16):8552–8557PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Herwald H, Dedio J, Kellner R, Loos M, Muller-Esterl W (1996) Isolation and characterization of the kininogen-binding protein p33 from endothelial cells. Identity with the gC1q receptor. J Biol Chem 271(22):13040–13047PubMedCrossRefGoogle Scholar
  125. 125.
    Schmaier AH (2016) The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities. J Thromb Haemost 14(1):28–39. doi: 10.1111/jth.13194 PubMedCrossRefGoogle Scholar
  126. 126.
    Mahdi F, Madar ZS, Figueroa CD, Schmaier AH (2002) Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. Blood 99(10):3585–3596PubMedCrossRefGoogle Scholar
  127. 127.
    Joseph K, Tholanikunnel BG, Ghebrehiwet B, Kaplan AP (2004) Interaction of high molecular weight kininogen binding proteins on endothelial cells. Thromb Haemost 91(1):61–70. doi: 10.1160/TH03-07-0471 PubMedGoogle Scholar
  128. 128.
    Renne T, Schuh K, Muller-Esterl W (2005) Local bradykinin formation is controlled by glycosaminoglycans. J Immunol 175(5):3377–3385PubMedCrossRefGoogle Scholar
  129. 129.
    Ravindran S, Grys TE, Welch RA, Schapira M, Patston PA (2004) Inhibition of plasma kallikrein by C1-inhibitor: role of endothelial cells and the amino-terminal domain of C1-inhibitor. Thromb Haemost 92(6):1277–1283. doi: 10.1160/TH04-01-0008 PubMedGoogle Scholar
  130. 130.
    Joseph K, Tholanikunnel BG, Kaplan AP (2002) Activation of the bradykinin-forming cascade on endothelial cells: a role for heat shock protein 90. Int Immunopharmacol 2(13–14):1851–1859PubMedCrossRefGoogle Scholar
  131. 131.
    Joseph K, Tholanikunnel BG, Kaplan AP (2002) Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proc Natl Acad Sci U S A 99(2):896–900. doi: 10.1073/pnas.022626899 PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Shariat-Madar Z, Mahdi F, Schmaier AH (2002) Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem 277(20):17962–17969. doi: 10.1074/jbc.M106101200 PubMedCrossRefGoogle Scholar
  133. 133.
    Mayhan WG (1994) Nitric oxide accounts for histamine-induced increases in macromolecular extravasation. Am J Phys 266(6 Pt 2):H2369–H2373Google Scholar
  134. 134.
    Duran WN, Beuve AV, Sanchez FA (2013) Nitric oxide, S-nitrosation, and endothelial permeability. IUBMB Life 65(10):819–826. doi: 10.1002/iub.1204 PubMedPubMedCentralCrossRefGoogle Scholar
  135. 135.
    Nielsen EW, Johansen HT, Hogasen K, Wuillemin W, Hack CE, Mollnes TE (1996) Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema. Immunopharmacology 33(1–3):359–360PubMedCrossRefGoogle Scholar
  136. 136.
    Bossi F, Fischetti F, Pellis V, Bulla R, Ferrero E, Mollnes TE, Regoli D, Tedesco F (2004) Platelet-activating factor and kinin-dependent vascular leakage as a novel functional activity of the soluble terminal complement complex. J Immunol 173(11):6921–6927PubMedCrossRefGoogle Scholar
  137. 137.
    Bouillet L, Mannic T, Arboleas M, Subileau M, Massot C, Drouet C, Huber P, Vilgrain I (2011) Hereditary angioedema: key role for kallikrein and bradykinin in vascular endothelial-cadherin cleavage and edema formation. J Allergy Clin Immunol 128(1):232–234. doi: 10.1016/j.jaci.2011.02.017 PubMedCrossRefGoogle Scholar
  138. 138.
    Czucz J, Schaffer G, Csuka D, Walentin S, Kunde J, Prohaszka Z, Farkas H, Cervenak L (2012) Endothelial cell function in patients with hereditary angioedema: elevated soluble E-selectin level during inter-attack periods. J Clin Immunol 32(1):61–69. doi: 10.1007/s10875-011-9606-7 PubMedCrossRefGoogle Scholar
  139. 139.
    Kajdacsi E, Jani PK, Csuka D, Varga LA, Prohaszka Z, Farkas H, Cervenak L (2014) Endothelial cell activation during edematous attacks of hereditary angioedema types I and II. J Allergy Clin Immunol 133(6):1686–1691. doi: 10.1016/j.jaci.2013.12.1072 PubMedCrossRefGoogle Scholar
  140. 140.
    Demirturk M, Gelincik A, Cinar S, Kilercik M, Onay-Ucar E, Colakoglu B, Arda N, Buyukozturk S, Deniz G (2014) Increased eNOS levels in hereditary angioedema. Int Immunopharmacol 20(1):264–268. doi: 10.1016/j.intimp.2014.03.007 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of MedicineUniversity of CaliforniaLa JollaUSA
  2. 2.San Diego Veterans Administration Healthcare SystemSan DiegoUSA

Personalised recommendations